Get the Stockscreener App
2.28
6.94%
-0.17
BiomX Inc stock is traded at $2.28, with a volume of 140.72K.
It is down -6.94% in the last 24 hours and down -68.11% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$2.45
Open:
$2.47
24h Volume:
140.72K
Relative Volume:
2.01
Market Cap:
$3.48M
Revenue:
-
Net Income/Loss:
$-23.14M
P/E Ratio:
-2.2505
EPS:
-1.0131
Net Cash Flow:
$-29.23M
1W Performance:
-55.90%
1M Performance:
-68.11%
6M Performance:
-71.43%
1Y Performance:
-80.94%
1-Day Range:
$2.22
$2.535
1-Week Range:
$2.22
$3.9684
52-Week Range:
$2.22
$22.06
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Compare PHGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
2.28 | 3.74M | 0 | -23.14M | -29.23M | -1.0131 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
BiomX Discontinues Study and Files for Insolvency - TipRanks
BiomX Inc. Discontinues Phase 2b Study and Initiates Insolvency Proceedings - TradingView — Track All Markets
BiomX (NYSE: PHGE) subsidiary seeks insolvency as Phase 2b study ends, BX011 program retained - Stock Titan
BiomX Discontinues Phase 2b Trial for BX004 - The Globe and Mail
Healthy Upside Potential: BiomX Inc (PHGE) - setenews.com
BiomX Halts Phase 2b Trial Of BX004 In Cystic Fibrosis On High Rates Of Adverse Events - Nasdaq
Stocks Tumble As Bad News Hits Biotech And Energy Sectors - Finimize
BiomX Discontinues Phase 2b Clinical Trial for BX004 - TradingView
BiomX (PHGE) Halts Phase 2b Trial and Implements Cost-Saving Str - GuruFocus
BiomX announces discontinuation of phase 2b Bx004 trial following internal review - marketscreener.com
BiomX (NYSE American: PHGE) halts BX004 CF trial, to cut costs, weigh options - Stock Titan
BiomX discontinues phase 2b trial for BX004 - MSN
BiomX (PHGE) Price Target Increased by 964.52% to 168.30 - Nasdaq
BiomX (PHGE) Stock Analysis Report | Financials & Insights - Benzinga
Why BiomX Inc. stock could be top winner2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
How BiomX Inc. stock performs in high volatility marketsJuly 2025 Update & Daily Price Action Insights - Newser
How BiomX Inc. stock reacts to Fed tighteningJuly 2025 Update & AI Forecasted Entry/Exit Points - Newser
How BiomX Inc. stock compares with tech leadersJuly 2025 Review & Technical Pattern Alert System - Newser
How forex fluctuations impact BiomX Inc. stockWeekly Stock Recap & High Yield Equity Trading Tips - Newser
Is BiomX Inc. stock ideal for retirement investorsMarket Growth Report & Comprehensive Market Scan Reports - Newser
How BiomX Inc. stock behaves in tightening cyclesAnalyst Downgrade & Safe Entry Trade Signal Reports - Newser
BiomX provides update on BX004 Phase 2b trial in Cystic Fibrosis - MSN
BiomX announces 1-for-19 reverse stock split - MSN
H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries - Investing.com Canada
HC Wainwright Issues Optimistic Estimate for BiomX Earnings - Defense World
BiomX (NYSEAMERICAN:PHGE) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
BiomX (NYSEAMERICAN:PHGE) Price Target Raised to $26.00 at HC Wainwright - Defense World
HC Wainwright Forecasts Strong Price Appreciation for BiomX (NYSEAMERICAN:PHGE) Stock - Defense World
HC Wainwright Boosts BiomX (NYSEAMERICAN:PHGE) Price Target to $26.00 - Defense World
HC Wainwright & Co. Reiterates BiomX (PHGE) Buy Recommendation - Nasdaq
PHGE: HC Wainwright & Co. Reiterates Buy Rating with $26 PT | PH - GuruFocus
Why Is BiomX Stock Falling Today?BiomX (AMEX:PHGE) - Benzinga
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review - Sahm
BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026 - Nasdaq
BiomX Says Working to Lift FDA Hold Concerning Nebulizer Device in Phase 2b Study of BX004 for Cystic Fibrosis - marketscreener.com
FDA Review Delays BiomX's (PHGE) Cystic Fibrosis Trial Progress - GuruFocus
BiomX Updates on Phase 2b Study for BX004 - TipRanks
BiomX Updates on FDA Clinical Hold and Study Progress - TradingView
BiomX (NYSE American: PHGE) DMC Backs BX004 Phase 2b Study, Topline Expected 2026 - Stock Titan
PHGE: HC Wainwright Raises Price Target for BiomX to $26.00 | PH - GuruFocus
HC Wainwright & Co. Maintains BiomX (PHGE) Buy Recommendation - Nasdaq
BiomX price target adjusted to $26 from $15 at H.C. Wainwright - TipRanks
Stock splits calendar for: - Yahoo Finance Singapore
BiomX announces FDA feedback on development pathway for BX011 - MSN
BiomX Inc. Reports Q3 2025 Financial Results and Program Updates - MSN
BiomX Inc. Earnings Call: Progress Amid Challenges - MSN
Why BiomX Inc. stock stays undervaluedJuly 2025 Trends & Precise Swing Trade Entry Alerts - newser.com
BiomX Stock to Reverse Split on Tuesday, November 25th (NYSEAMERICAN:PHGE) - Defense World
BiomX Stock to Reverse Split on Tuesday, November 25th (NYSEMKT:PHGE) - Defense World
BiomX Inc. COmmon Stock (NYSE:PHGE) Stock Quote - Markets Financial Content
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):